CAV1 and neoplasm: These findings, the evidence of an inhibitory action of TGF-β1 on CAV-1 expression in CAFs [128], and the commonality between the phenotype of myofibroblasts from neoplastic and non-neoplastic diseases [99], makes it highly probable that the suppressive action of TGF-β1 on CAV-1 expression in CAFs is also brought about via modification of the histone H3K4Me3 mark at the promoter site of the CAV-1 gene.